GlassScriptPhysician profile
Matthew J Sheaffer
NPI 1871879387
$2,591.98
in general payments reported to CMS, 2019-2025
26 companies · $210 in 2025
The $210 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $507 · 2022: $581 · 2023: $949 · 2024: $345 · 2025: $210.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,399 · Consulting Fee: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,399.15 |
| Consulting Fee | $105.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $408.91 | 2021-2023 | |
| Janssen Pharmaceuticals, INC | $331.75 | 2021-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $318.33 | 2021-2025 | Lifevest |
| Medtronic, INC. | $307.57 | 2022-2025 | Micra, Linq II, Cobalt Dr Mri Surescan |
| Merck Sharp & Dohme LLC | $238.95 | 2021-2023 | Verquvo |
| E.R. Squibb & Sons, L.L.C. | $202.42 | 2021-2023 | Camzyos, Eliquis |
| Philips North America LLC | $157.67 | 2022-2025 | Ambulatory Monitoring & Diagnostics Undivided, (Ck4) Mcot |
| Irhythm Technologies, INC. | $88.49 | 2022-2023 | Zio Xt Patch |
| Kiniksa Pharmaceuticals, LTD. | $60.97 | 2021-2023 | Arcalyst |
| Pfizer INC. | $58.06 | 2022-2025 | |
| Abbott Laboratories | $52.24 | 2021-2022 | |
| Cardiva Medical, INC. | $39.62 | 2024-2025 | Cardiva Vascade Mvp Vvcs 6-12f |
| Amgen INC. | $39.01 | 2021 | |
| Sanofi-Aventis U.S. LLC | $35.60 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.27 | 2021-2022 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $31.89 | 2021-2023 | Brilinta |
| Lexicon Pharmaceuticals, INC. | $31.61 | 2023 | Inpefa |
| Baxter Healthcare | $28.46 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Chiesi USA, INC. | $18.85 | 2021 | |
| Daiichi Sankyo INC. | $18.70 | 2023 | Injectafer |
| Altathera Pharmaceuticals LLC | $18.37 | 2025 | Sotalol Hydrochloride |
| Novo Nordisk INC | $15.59 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.82 | 2022 | |
| Boston Scientific Corporation | $14.42 | 2021 | |
| Glaxosmithkline, LLC. | $13.52 | 2025 | Arexvy, Shingrix |
| Genzyme Corporation | $12.89 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Sheaffer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.